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Deficiency of complement factor I is a rare immunodeficiency that typically presents with
increased susceptibility to encapsulated bacterial infections. However, non-infectious
presentations including rheumatological, dermatological and neurological disease are
increasingly recognized and require a high-index of suspicion to reach a timely
diagnosis. Herein, we present two contrasting cases of complement factor I deficiency:
one presenting in childhood with invasive pneumococcal disease, diagnosed using
conventional immunoassays and genetics and the second presenting in adolescence
with recurrent sterile neuroinflammation, diagnosed via a genomic approach. Our
report and review of the literature highlight the wide spectrum of clinical presentations
associated with CFI deficiency and the power of genomic medicine to inform rare
disease diagnoses.
Keywords: complement factor I, primary immunodeficiency, genomic medicine, pneumococcal infection,
neuroinflammation, complement deficiency
INTRODUCTION
The human complement system is a tightly regulated cascade of soluble and membrane-
bound proteins that maintains immune homeostasis by clearing apoptotic cells and immune
complexes, and facilitates host defense via the opsonization and direct killing of microbial
pathogens. Monogenic deficiencies of complement factors can result in susceptibility to
infection by encapsulated bacteria and, in some cases, systemic lupus erythematosus-like disease,
glomerulonephropathies and vasculitides.
Complement factor I (CFI) is an 88 kDa glycoprotein that is principally produced by the
liver. It circulates in a zymogen-like state prior to activation by furin (1), which cleaves a linker
from CFI to produce a heterodimeric protein formed of a 55 kDa heavy chain and 37 kDa light
chain joined by a single disulphide bond. CFI is recruited to sites of complement deposition
where regulatory proteins act as co-factors for its enzymic activity. When acting with a co-factor
protein (complement factor H, CD46, C4 binding protein, or CD35), CFI binds and sequentially
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cleaves C3b into iC3b, C3c, C3dg, and finally C3d (2). CFI and
can similarly cleave C4b. The cleavage products of C3 and C4
lack the capacity to form C3 convertases that further amplify
the complement cascade but continue to facilitate the removal
of immune complexes. Thus, CFI acts as an essential regulator of
classical and alternative complement cascade activation.
The understanding of the spectrum of disease associated with
deficiency of complement factor I has broadened considerably
in recent years. Herein, we report two contrasting cases of
complement factor I deficiency; one presenting with spontaneous
pneumococcal peritonitis in childhood and the other presenting
with recurrent, sterile neuroinflammation in adolescence.
CASE 1
A 2-year-old girl (patient A) presented to the emergency
department with a 24-h history of lethargy, fever and abdominal
pain. One week previously, she had suffered from a mild
gastroentritis-like illness but had recovered fully. She was a
dichorionic-diamniotic twin born at 33 weeks, was previously
well and fully vaccinated according to the UK schedule,
including neonatal BCG. There was no family history of
immunodeficiency (Figure 1A).
On admission, she had a distended abdomen, tachycardia,
pyrexia (39◦C) and raised inflammatory markers; she was
admitted and treated as suspected appendicitis. At laparotomy,
frank pus was found in the abdomen but the appendix appeared
grossly normal. A diagnosis of spontaneous bacterial peritonitis
was made. Blood cultures from admission grew serotype 10A
S. pneumoniae, a strain not contained within the 13-valent
pneumococcal conjugate vaccine administered to children in
the UK.
Routine investigation of pediatric invasive pneumococcal
disease in our center is based on the protocol described by
Gashinard et al. (3). The patient’s results are summarized
in Table 1 and Supplementary Table 1. The beta-2 peak on
serum electrophoresis was absent, commensurate with low C3
(Figure 1B). Significantly reduced activity of both the classical
and alternative complement pathways was noted and subsequent
investigation demonstrated completely absent CFI and reduced
levels of complement factors B and H indicative of consumption.
The clinical diagnosis was confirmed by Sanger sequencing of
CFI (NM_000204.4) in the proband, which revealed compound
heterozygous variants (c.129C>A; p.Cys43∗ and c.559C>T;
p.Arg187∗, Figure 1C) predicting protein truncation within
the factor I membrane attack complex (FIMAC) domain
and scavenger receptor cysteine rich domain, respectively
(Figure 1D). The p.Cys43∗ variant has not previously been
reported, however the p.Arg187∗ variant has been identified in
Abbreviations: AHLE, acute haemorrhagic leukencephalitis; CADD, combined
annotation dependent depletion; CFI, complement factor I; CSF, cerebral
spinal fluid; DWI, diffusion weighted imaging; gnoMAD, genome aggregation
database; FIMAC, factor I membrane attack complex; FFP, fresh frozen plasma;
IVIG, intravenous immunoglobulin; mCSM, mutation cutoff scanning matrix;
MRI, magnetic resonance imaging; PCR, polymerase chain reaction; PTPRC,
protein tyrosine phosphatase receptor C; SIFT, sorting intolerant from tolerant;
SRCR, scavenger receptor, cysteine rich; WCC, white cell count; WGS, whole
genome sequencing.
two individuals with complete CFI deficiency, on each occasion
in trans with a frameshifting allele (Table 1). The p.Arg187∗
variant has an allele frequency of 0.00001415with no homozygote
identified in gnomAD.
The patient remains well at 5 years and 4 months of
age, and has had no further invasive bacterial infections
following initiation of prophylactic antibiotics. Vaccination
against encapsulated bacteria including H. influenzae type b,
pneumococcus and meningococcus were optimized with good
responses (Supplementary Table 1). Complement levels and
function in the proband’s twin were normal, excluding complete
CFI deficiency, however he was found to be heterozygous for the
129C>A variant.
CASE 2
A 32 year old lady (patient B) presented to the emergency
department with a 3 day history of gradual onset frontal
headache, blurred vision and slurred speech, followed by
several tonic-clonic seizures in short succession, deteriorating
into coma. Her family reported preceding upper respiratory
tract infection symptoms. She was admitted and treated as
presumed meningoencephalitis. MRI neuroimaging showed
diffuse, confluent cerebral and cerebellar white matter high
signal changes, oedema, and mass effect without DWI change
(Figure 2A). She had suffered three similar presentations in the
past; a severe episode aged 10 and two milder episodes at the
ages of 12 and 18. Her sister had died of fulminant haemorrhagic
leukencephalopathy at the age of 16 (Figure 2B). The family had
not been investigated further.
CSF sampling showed an inflammatory picture (WCC
322, 55% polymorphs), but no bacterial or viral pathogens
were detected by routine culture or PCR. C3 was borderline
low and acute phase proteins remained normal during her
illness. There was no improvement following treatment
with empirical antibiotics and antivirals but a slow recovery
ensued following pulsed methylprednisolone, with no residual
neurological though very mild cognitive deficit. Whole
genome sequencing (WGS) was undertaken in the proband
and the proband’s unaffected mother to achieve a unifying
diagnosis. Filtering of all the variants identified by WGS
based on quality metrics, deleteriousness, inheritance pattern
and biological function led to a short list of 5 genes that
were investigated further (Supplementary Figures 1, 2). Of
these, the CFI gene was the only gene to show the expected
compound heterozygosity.
WGS revealed two heterozygous variants in CFI (c.191C>T;
p.P64L and c.262C>A; p.Q88K) lying within the CFI FIMAC
domain (Figure 1D). Although paternal DNA was not available,
Illumina read-level information was used to confirm the variants
lay in trans (Figure 2C). The CADD score for the p.P64L
variant is 33.00, SIFT predicted the variant to be damaging
and PolyPhen2 predicted the variant to be probably damaging
with an allele frequency of 0.0002335; no homozygotes were
identified in gnomAD. P64 is highly conserved across taxa
(Supplementary Figure 3). Previous reports have associated the
p.P64L variant with atypical haemolytic uraemic syndrome
(21) and age related macular degeneration (22). The p.Q88K
Frontiers in Immunology | www.frontiersin.org 2 June 2019 | Volume 10 | Article 1150
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FIGURE 1 | (A) Pedigree of Patient A. (B) Capillary zone electrophoresis trace from Patient A demonstrating absent beta-2 peak. (C) Sequencing chromatograms
from Patient A demonstrating c.129C>A and c.559C>T mutations in the heterozygous states. Codon positions and wild-type amino-acids are indicated below. (D)
Schematic of the domain structure of complement factor I protein demonstrating position of mutations from Patient A (black) and Patient B (blue).
variant has not been reported previously. Although the CADD
score for p.Q88K was only 7.34 and SIFT predicted the
variant to be tolerated, Polyphen2 predicted the variant to be
possibly damaging. Q88 is also highly conserved across taxa
(Supplementary Figure 3).
To further assess the pathogenicity of these variants, mutation
Cutoff Scanning Matrix (mCSM) analysis was performed
(Figure 2D), an approach that predicts the effects of amino
acid variation on protein stability by estimating free energy
changes (23). Using the CFI crystal structure solved to
2.7 Å (24), mCSM analysis predicted a destabilizing effect
of both the p.P64L and p.Q88K variants with 11G of
−0.715 and −0.844 kcal/mol, respectively. Three-dimensional
modeling of the protein structure of CFI in complex with
C3b shows the close topological relationship between the P64
and Q88 residues of CFI and the V1658 residue of C3b
(Figure 3A). Furthermore, the G71 residue, mutations of which
have also been associated with neurological presentations of
CFI deficiency (7), lies on a side chain between these two
mutations Figure 3B.
Consistent with these in silico prediction, factor I levels were
measured in the proband and found to be undetectable.
Commensurate reductions in functional activity of the
classical and alternative pathway were also identified
(Supplementary Table 1) confirming the genomic diagnosis.
DNA from the deceased sibling was not available for testing.
Heterozygous variants in three other immunologically relevant
genes were identified by WGS in Patient B: C6, PTPRC and
CD74 (Supplementary Figure 2). The heterozygous variant
in C6 illustrates the challenges of interpreting variants based
exclusively on bioinformatic predictive scores. Although the
CADD score for this variant is 15.1, serum concentrations of
the terminal complement complex are elevated in patient B,
the assembly of which could not occur without functioning
C6. Furthermore, deficiencies in the terminal complement
cascade are associated with meningococcal infections, which
were not a feature in the clinical presentation. The heterozygous
variant identified in PTPRC is unlikely to be clinically relevant
given PTPRC variants are associated with severe combined
immunodeficiency and the variant was also identified in the
healthy mother. The heterozygous variant in CD74 has CADD
score of 34; CD74 encodes the class II invariant chain that
facilitates peptide loading within the endoplasmic reticulum.
Immunodeficiency associated with CD74 variants have not
been described.
DISCUSSION
Complete CFI deficiency is a rare immunodeficiency with 32
genetically characterized cases arising in 27 separate kindreds in
the literature (Table 1). By far the most common presentation
of complete CFI deficiency is susceptibility to invasive bacterial
infections (S. pneumoniae, N. meningitidis, H. influenzae)
affecting 81.25% of individuals. The remainder present with
a range of rheumatological, neurological and dermatological
manifestations. Within the genetically confirmed cases, there is
Frontiers in Immunology | www.frontiersin.org 3 June 2019 | Volume 10 | Article 1150
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TABLE 1 | Summary of clinical and immunological characteristics of published, genetically confirmed cases of CFI deficiency.
Case Age at first
presentation
(yr)
Family Gender Origin Allele 1 Allele 2 Protein 1 Protein 2 Domain 1 Domain 2 Infections Other
manifestations
CFI CFH CFB C3 AP50 CH50 References Notes
1 10 1 F British c.191C>T c.262C>A p.P64L p.Q88K FIMAC FIMAC Recurrent
haemorrhagic
leukoencephalitis
Undetectable n/a n/a 0.43 g/l <50% 876
(1,000–
2,000)
This
publication
2 n/a 2 F Turkish c.162C>G Homozygous p.C54W Homozygous FIMAC FIMAC Leukocytoclastic
vasculitis
<5% 47.00% <3% 0.29 g/L 0.00% 21.00% (4)
3 2 3 M Australian c.133-
134delAA
Homozygous p.K45Sfs*11 Homozygous FIMAC FIMAC Recurrent
infections with
S. pneumoniae
and S.
pyogenes
including
septicaemia,
joint infections
and pneumonia
Juvenile idiopathic
arthritis
Undetectable 189 mg/L
(345–590)
<38 mg/L
(191–382)
0.32 g/L
(0.7–2.06)
Undetectable 41.00% (5)
4 Childhood 3 M Australian c.133-
134delAA
Homozygous p.K45Sfs*11 Homozygous FIMAC FIMAC Otitis media Undetectable 148 mg/L
(345–590)
<38 mg/L
(191–382)
0.22 g/L
(0.7–2.06)
Undetectable 11.00% (5)
5 n/a 4 F Spanish c.80_81delAT c.559C>T p.D27Afs*18 p.R187* FIMAC SRCR Meningitis,
penumonia
Henoch-Schonlein
purpura
0 9.4 mg/dl
(12–56)
0 mg/dL
(7.5–28)
38.4 n/a n/a (6)
6 10 5 F Filipino n/a n/a p.G71V p.C196S FIMAC SRCR Diffuse vasogenic
cerebral oedema,
neutrophilic brain
infiltration
4.6 mcg/ml
(29–59)
107
mcg/ml
(160–412)
43.8 mcg/ml
(127.6–278.5)
41 <10% 21 U/ml
(30–75
U/ml)
(7) Asymptomatic
younger
sister with
same
compound
heterozygous
mutations
and
complement
profile
7 2 6 F Brazilian/
Portuguese
c.129C>A c.559C>T p.C43* p.R187* FIMAC SRCR Spontaneous
pneumococcal
peritonitis
Undetectable 211.0
mg/L
(345–590)
29.7 mg/L
(295–400)
21 mg/dL 21.00% 20.00% This
publication
8 10 7 M Filipino n/a n/a p.G71V Heterozygote FIMAC Vasogenic cerebral
oedema, neutrophilic
cerebral inflammation
6 mcg/ml
(29–59)
136
mcg/ml
(160–412)
n/a <40 29.00% 40 U/ml
(30–75
U/ml)
(7)
9 n/a 8 F Spanish c.559C>T c1610_
1611insAT
p.R187* p.V537Vfs*2 SRCR SP Pneumonia,
facial cellulitis
Hypocomplementemic
vasculitis
4.00% 4.8 mg/dl
(12–56)
0 mg/dL
(7.5–28)
31.5 n/a n/a (6) Asymptomatic
younger
sister with
same
compound
heterozygous
mutations
and
complement
profile
10 1m 9 F Denmark c.563G>T c.1253A>T p.G188V p.H418L SRCR SP Recurrent
bacterial upper
respiratory tract
infections,
septicaemia,
erysipelas
Undetectable 64%
(69–154)
<2.5%
(59–154)
48.00% Reduced Reduced (8)
11 Childhood 10 M Spanish c.485G>A Homozygous p.G162D Homozygous SRCR SRCR Streptococcus
bovis
endocarditis,
pneumonias,
meningitis,
sepsis
Undetectable 26.3
mg/dl
(12–56)
4.5 mg/dL
(20–40)
29.6 0.00% <12.1
U/ml
(9)
12 n/a 11 M Spanish c. 772 G>A c. 772 G>A p.D220-
K257del
p.D220-
K257del
LDRA1 LDRA1 Pneumonia,
meningococcal
septicaemia,
oral thrush,
balanitis
0.00% 8.40
mg/dl
(12–56)
0 mg/dL
(7.5–28)
22.6 n/a n/a (6)
(Continued)
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TABLE 1 | Continued
Case Age at first
presentation
(yr)
Family Gender Origin Allele 1 Allele 2 Protein 1 Protein 2 Domain 1 Domain 2 Infections Other
manifestations
CFI CFH CFB C3 AP50 CH50 References Notes
13 16 12 F Spanish c.739T>G Homozygous p.C247G Homozygous LDRA1 LDRA1 Recurrent
meningitis
coinciding with
menstruation
n/a 52
mcg/ml
(200–600)
6.7 mg/dL
(17–60)
24 mg/dl n/a <50 U/ml (10, 11)
14 18 12 F Spanish c.739T>G Homozygous p.C247G Homozygous LDRA1 LDRA1 Meningitis,
recurrent
tonsillitis
3.00% 65
mcg/ml
(200–600)
7.3 mg/dl
(17–60)
22 mg/dl n/a <50 U/ml (10, 11)
15 2 13 F Spanish c.772G>A Homozygous p.D220-
K257del
Homozygous LDRA1 LDRA1 Meningococcal
meningitis,
pneumococcal
meningitis
Hyperpigmented skin
lesions
n/a 100
mcg/ml
(200–600)
<12 md/dL
(17–60)
16.5
mg/dl
n/a 140 U/ml
(200–400
U/ml)
(10)
16 31 13 M Spanish c.772G>A Homozygous p.D220-
K257del
Homozygous LDRA1 LDRA1 Lymphoid
meningitis
Hyperpigmented skin
lesions
n/a 80
mcg/ml
(200–600)
n/a 24.7
mg/dl
n/a 136 U/ml
(200–400
U/ml)
(10)
17 9 13 M Spanish c.772G>A Homozygous p.D220-
K257del
Homozygous LDRA1 LDRA1 Otitis, septic
arthritis
Hyperpigmented skin
lesions
n/a 60
mcg/ml
(200–600)
<12 md/dL
(17–60)
17.3
mg/dl
n/a 142 U/ml
(200–400
U/ml)
(10)
18 4 14 F Turkish c.764G>A Homozygous p.C255Y Homozygous LDRA1 LDRA1 Recurrent
upper and
lower
respiratory tract
infections,
meningitis
Recurrent vasculitic
eruptions, immune
complex
glomerulonephritis,
microscopic
haematuria
Undetectable 48%
(69–154)
<12%
(59–154)
0.48 g/L
(0.77–
1.38)
Undetectable Normal
range
(8, 12) 2 female
siblings
share
genotype—
disease
manifestations
not reported;
1 female
sibling died
of sepsis at
18m but
DNA was not
available
19 n/a
(diagnosed
at 23)
15 F Swedish c.748C>A c.803C>T p.Q250K p.S268K LDRA1 LDRA2 Systemic lupus
erythematosus
2.00% 85%
(69–154)
44% (59–154) 63.00% Reduced Normal
range
(8)
20 10 16 F Croatia c.772G>A c.1100T>G p.D220-
K257del
p.I357M LDRA1 SP Pneumonia,
recurrent upper
respiratory tract
infections
Undetectable 81%
(69–154)
13% (59–154) 73.00% Normal Reduced (8)
21 n/a
(diagnosed
at 18)
17 F Turkish c.866A>T Homozygous p.D289V Homozygous LDRA2 LDRA2 Recurrent
upper and
lower
respiratory tract
infections
Recurrent vasculitic
eruptions and
arthralgias
Undetectable 65%
(69–154)
∼10%
(59–154)
0.47 g/L
(0.7–2.06)
Undetectable 13.00% (5)
22 5 18 M Spanish c.1420 C>T 5.6 kB gene
deletion
p.R474* - SP - Meningitis with
meningococcal
septicaemia,
otitis
0.00% 19.5
mg/dl
(12–56)
0 mg/dL
(7.5–28)
33.4 n/a n/a (6) Asymptomatic
younger
brother with
same
compound
heterozygous
mutations
and
complement
profile
23 4m 19 F UK c.1253A>T c.772G>A p.H418L p.D220-
K257del
SP LDRA1 Pneumococcal
meningitis,
recurrent
meningococcal
meningitis,
otitis media
Undetectable n/a 10.00% 30.00% Undetectable 14 U/ml
(28–45
U/ml)
(13, 14)
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TABLE 1 | Continued
Case Age at first
presentation
(yr)
Family Gender Origin Allele 1 Allele 2 Protein 1 Protein 2 Domain 1 Domain 2 Infections Other
manifestations
CFI CFH CFB C3 AP50 CH50 References Notes
24 2 20 F Pakistani c.1139A > G Homozygous p.H380R Homozygous SP SP Otitis media,
lower
respiratory tract
infection
Cutaneous vasculitis,
arthralgia
36% (19 mg/L) 219 mg/L
(36%)
n/a 22 0.00% 5.00% (15) Asymptomatic
older brother
with same
homozygous
mutations
and
complement
profile
25 16 21 F Belgian c. 1019 T>C c. 1571 A>C p.I340T p.D524V SP SP Aseptic
meningoencephalitis,
leukocutaneous
vasculitis
44 mg/L
(25–44)
460 mg/L
(360–680)
1 mg/dL
(8–21)
57 0.00% 97.00% (16)
26 4 22 F Pakistani c.1139A>G Homozygous p.H380R Homozygous SP SP Otitis media Recurrent abdominal
pain
2.5 mg/dL 35.5
mg/dl
(12–56)
1.2 mg/dL
(20–40)
35.2 0.00% <12.1
U/ml
(9) Asymptomatic
younger
brother with
same
homozygous
mutation,
absent factor
I but normal
C3
27 18m 23 M Scottish c.1253A>T Homozygous p.H418L Homozygous SP SP Staphylococcus
epidermidis
septic arthritis,
meningococcal
meningitis,
recurrent
sinusitis, facial
cellulitis
Undetectable 46.00% Undetectable 28.00% Undetectable Undetectable (13, 17) Asymptomatic
older sister
with same
homozygous
mutation
28 Childhood 24 M Spanish c.1450_
1454del
CTTCA
Homozygous p.L484Vfs*3 Homozygous SP SP Otitis media,
pharyngitis,
invasive
meningococcal
infection,
infected sacral
cyst
Undetectable 19.14
mg/dL
(12–56)
0.77 mg/dL
(20.5–40)
19.3
mg/dl
Undetectable 2 UI/ml
(34–71
UI/ml)
(18)
29 15m 25 F Brazilian c.1176insAT Homozygous p.W393Yfs*5 Homozygous SP SP Post-operative
infection,
bacterial
meningitis,
otitis,
pneumonia
Henoch-Schonlein
purpura and
subsequent systemic
lupus erythematosus:
diffuse proliferative
membranous
glomerulonephritis,
psychosis, seizures,
stroke, photosensitive
malar rash
Undetectable 93 (454 ±
124
mcg/ml)
Undetectable 127 ug/ml
(1,300–
1,500)
Undetectable Undetectable (19, 20)
30 3 25 F Brazilian c.1176insAT Homozygous p.W393Yfs*5 Homozygous SP SP Adenoid
hyperplasia,
gastrointestinal
infection
progressing to
fatal severe
bilateral
pneumonia
Undetectable 105 (454
± 124
mcg/ml)
Undetectable 259 ug/ml
(1,300–
1,500)
Undetectable Undetectable (19, 20)
31 3m 26 F Argentinian c.1006C>T Homozygous p.Q354* Homozygous SP SP Otitis media,
recurrent
pneumonia
Recurrent vasculitis Undetectable 100%
(69–154)
<12%
(59–154)
39.00% Reduced Reduced (8)
32 4 27 F Spanish c.1176_
1177dupAT
c.485G>A p.W393Yfs*5 p.G162D SP SRCR Otitis, sinusitis,
bronchitis,
meningococcal
septicaemia
Arthritis 2.00% 8.23
mg/dl
(12–56)
0 mg/dL
(7.5–28)
22.8 n/a n/a (6)
FIMAC, factor I membrane attack complex; SRCR, scavenger receptor cysteine rich; SP, serine protease; LRDA, low density lipoprotein receptor class A domain.
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FIGURE 2 | (A) T2 weighted MRI imaging from Patient B during acute encephalomyelitis and following treatment with pulsed methylprednisolone. (B) Pedigree of
Patient B showing genotypes of rare CFI variants. NA, DNA not available for deceased individuals. (C) Visualization of read-level information shows that the two CFI
variants, lying 71 bp apart, are easily phased by the 150 bp reads and are in trans (boxed). The absence of the c.191C>T variant in the mother (lower panel) is
insufficient to confirm an in trans orientation as the variant may have arisen de novo. (D) Free energy change calculations for known missense, disease-causing point
mutations in complement factor I with mutations from Patient B shown in red.
FIGURE 3 | Three-dimensional topology of selected missense mutations in complement factor I (light gray) and their relationship with C3b (dark gray). (A) P64 residue
of complement factor I forms a contact point with V1658 of C3b (blue). Q88 lies in close apposition to this contact site. (B) G71 (previously reported by Broderick et al
and associated with a similar clinical phenotype) lies on a side chain between P64 and Q88. Figures produced using PyMOL v2.2 using a crystal structure of CFI and
C3b solved to a resolution of 4.2 Å (Protein Data Bank Reference – 5O32).
a slight female preponderance (2.2:1) and the deficiency typically
presents in childhood, although significant diagnostic delay, as
seen in Patient B, can occur.
No clear relationship currently exists between mutations
in CFI and the resulting clinical phenotype of complete CFI
deficiency. Factor I activity is dependent on its heavy chain which
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contains complement regulatory elements, its light chain which
contains the serine protease domain, hydrophobic interactions
between the heavy and light chain and the presence of a co-factor
(e.g., CD35, CD46, or complement factor H) (2, 25). Different
co-factors facilitate different patterns of C3b cleavage by CFI (2).
The clinical phenotype driven by CFI variants will, therefore,
depend on how the structural relationships between CFI domains
and co-factors are disrupted, whether there is preferential gene
expression from different CFI alleles, environmental exposure to
pathogens and the individual’s underlying genetic architecture
that may confer susceptibility to infectious or non-infectious
manifestations of disease. This is illustrated by the observation
that within some of the kindreds described in Table 1, there are
siblings that share a CFI genotype with an affected proband but
remain asymptomatic.
Patient A, who presented with invasive pneumococcal disease
in childhood, had biallelic mutations predicted to truncate CFI
within the FIMAC and SRCR domains. Neither allele produces
a protein with any enzymic function, reflected by the patient’s
low C3, AP50, and CH50. Susceptibility to encapsulated bacterial
infection arises due to a secondary deficiency in C3 and inefficient
bacterial opsonization.
The management of infectious complications of complete
CFI deficiency is well-established and relies on the optimization
of vaccination against encapsulated bacteria and appropriate
use of prophylactic antibiotics. As CFI synthesis occurs in
the liver, bone marrow transplantation is not a variable
strategy to correct CFI deficiency. There is no empirical
evidence demonstrating the effectiveness of antibiotic
prophylaxis and vaccination in CFI deficiency, however,
reports suggest infection frequency reduces with age with
some individuals eventually becoming asymptomatic (8, 26).
Primary and secondary deficiencies of C3 have been associated
with reductions in circulating unswitched and switched
memory B cells, without obvious impairment of functional
antibody responses (26); close monitoring of functional
antibody responses to ensure preservation of immunity
against encapsulated organisms is strongly recommended in
these patients.
Recurrent sterile neuroinflammation without a significant
burden of infection, as seen in patient B, is an unusual
presentation of CFI deficiency. The variants identified in patient
B are predicted to affect the interface between CFI and C3b.
The P64 residue of CFI directly contacts C3b V1658 and
forms part of a larger hydrophobic patch on CFI involving
residues I55, V60, L63, P64, Y65, F82, P83, and L91 that
interacts with the hydrophobic residues V1657, V1658, F1659,
and the methylene groups K1570 and K1576 of C3b (2). P64L
is predicted to cause steric hindrance at the contact site with
C3b. Q88 is a buried residue that forms a hydrogen bond
with the carbonyl backbone of T98; the Q88K substitution
is predicted to abrogate this interaction however, the precise
structural consequences of this substitution are not clear. mCSM
analysis predicted a destabilizing effect and three-dimensional
modeling suggests Q88 has a close topological relationship with
P64. Although CFI was undetectable in patient B’s serum, C3
and CH50 were not reduced to the same degree as patient
A suggesting that these variants may leave CFI with some
residual function.
Four other variants in CFI have been associated with
severe neuroinflammatory presentations of CFI deficiency. G71V
has been identified in the heterozygous state in a patient
with acute haemorrhagic leukencephalitis suggesting it may
act in a dominant manner (7). G71 lies on a side chain
between residues that form the hydrophobic contact site for
C3b on CFI. G71V has also been found in the compound
heterozygous state with another variant, C196S, hypothesized
to disrupt a disulphide bond in the SRCR domain of CFI. The
final two variants associated with neurological presentations
of CFI deficiency are I340T and D524V (16). These variants
lie within the serine protease domain but do not directly
affect the CFI catalytic triad of H362, D411 and S507. I340T
and D524V in trans produce dysfunctional CFI proteins that
lacked activity to efficiently regulate alternative complement
cascade activation, but did not significantly impact the classical
cascade (16).
Together, these cases suggest that mutations that completely
abrogate the activity of CFI may lead to presentations dominated
by childhood infections but if residual activity is retained, more
unusual presentationsmay arise. Functional assays of CFI activity
are challenging given that CFI interacts with multiple cofactors,
but may be helpful in resolving the consequences of novel
variants identified by genomic technologies (27).
Optimum strategies for the management of neurological
presentations of CFI deficiency remain uncertain. Broderick et al
described two cases of acute haemorrhagic leukoencephalitis
(AHLE) secondary to complete CFI deficiency: a 10 year
old female initially responded to high-dose corticosteroids
and intravenous immunoglobulin (IVIG) but this was
ineffective during a relapse of the condition aged 17.
Anakinra significantly improved neurological parameters
and radiological appearances on that occasion and was
subsequently tapered. The same physicians successfully used a
combination of high-dose corticosteroids, IVIG and anakinra
to treat a 10 year old with ALHE; weaning of anakinra
was not possible due disease relapses (7). Haerynck et al.
described the case of a 16 year old girl with recurrent aseptic
meningoencephalitis treated with pulsed corticosteroids,
initially with good response but with disease relapses failing
to respond to plasmapheresis and requiring further treatment
with cyclophosphamide and mycophenolate mofetil (16).
Direct replacement of CFI using fresh frozen plasma (28) or
purified CFI (29, 30) have been attempted historically with
transient correction of in vitro assays of complement activity.
However, long-term clinical outcomes have not been reported
and FFP infusions have been associated with anaphylactic
reactions (31).
In conclusion, we report two cases of CFI deficiency with
quite different presentations and routes taken to diagnosis.
Common to both cases was the observation of low C3 and
normal C4, indicative of dysregulated complement consumption.
Cognizance of this unusual profile of complement tests and the
range of presentations of complete CFI deficiency may facilitate
timely diagnosis of this rare immunodeficiency.
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